N/A
Completed N=48
A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
Cervical dystonia · Blepharospasm
Source: ClinicalTrials.gov NCT01814774 ↗
Enrolled (actual)
48
Serious AEs
0.0%
Results posted
Jul 2014
Primary outcomePrimary: Dose of Botulinum Toxin Used to Treat Cervical Dystonia — 444.70; 536.30 units per patient per year
Summary
This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical practice.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Dose of Botulinum Toxin Used to Treat Cervical Dystonia |
444.70; 536.30 | — |
| PRIMARY Dose of Botulinum Toxin Used to Treat Blepharospasm |
50.40; 64.01 | — |
| SECONDARY Number of Participants With Adverse Events |
12; 10 | — |
| SECONDARY Botulinum Toxin Inter-injection Interval |
15.83; 14.39 | — |
Eligibility Criteria
Inclusion Criteria
- confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at least 2 years
- treatment with Xeomin® and BOTOX® for at least 1 year each
Exclusion Criteria
- having a neuromuscular junction transmission disorder or taking any medications that could affect neuromuscular junction transmission
- previous surgical procedure involving bone or muscle for the management of cervical dystonia or blepharospasm
Data sourced from ClinicalTrials.gov (NCT01814774). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.